Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011

MLA

Stacy E. Croteau, et al. “Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011.” Blood, vol. 140, Nov. 2022, pp. 1899–901. EBSCOhost, https://doi.org/10.1182/blood-2022-158903.

APA

Stacy E. Croteau, M. Elaine Eyster, Huyen Tran, Margaret V. Ragni, Benjamin J. Samelson-Jones, Lindsey George, Spencer Sullivan, John E.J. Rasko, Jill Moormeier, Pantep Angchaisuksiri, Jerome Teitel, Gili Kenet, Tung Wynn, Kristen Jaworski, Amy Macdougall, Savina Jaeger, Trupti Trivedi, Federico Mingozzi, Tiffany Chang, & Gallia Levy. (2022). Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011. Blood, 140, 1899–1901. https://doi.org/10.1182/blood-2022-158903

Chicago

Stacy E. Croteau, M. Elaine Eyster, Huyen Tran, Margaret V. Ragni, Benjamin J. Samelson-Jones, Lindsey George, Spencer Sullivan, et al. 2022. “Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011.” Blood 140 (November): 1899–1901. doi:10.1182/blood-2022-158903.